Latest Regulatory Challenges News

APA Group (ASX:APA) posted an 81% jump in net profit after tax to AUD 234 million for FY26, driven by strong EBITDA growth, cost savings, and contributions from new assets. The company declared its 22nd consecutive distribution increase, advancing key infrastructure projects and sustainability goals.

Fiducian Group posted solid underlying earnings growth in FY2026, boosted by a 7% rise in funds under management, advice and administration, while absorbing a one-off $7.95 million ASIC penalty that halved statutory profits.

WA Kaolin Limited has entered receivership with Cathro & Partners taking control, signalling urgent assessment of operations and potential sale or recapitalisation.

ASX Limited reported a 13.3% rise in operating revenue to $1.25 billion for FY26, with underlying net profit up 5.2%, despite a 3.5% dip in statutory profit due to significant one-off costs including a $20.5 million ASIC penalty. The company declared a fully franked final dividend of 104.7 cents per share and appointed Anthony Attia as CEO.

X2M Connect Limited (ASX:X2M) has launched a fully underwritten Share Purchase Plan (SPP) aiming to raise up to $1 million, offering eligible shareholders shares at a discount plus free options and bonus shares, subject to shareholder approval.

Fiducian Group's subsidiary Fiducian Investment Management Services Limited has settled ASIC civil proceedings with a $7.3 million penalty plus $650,000 in costs, approved by the NSW Supreme Court.

News Corp’s FY26 revenue rose 7% to $9.03 billion, driven by Digital Real Estate Services and Dow Jones, while net income from continuing operations increased 15% to $743 million.

Block, Inc. delivered a robust Q2 2026 with 25% gross profit growth, driven by strong Cash App and Square performances, and raised its full-year guidance reflecting accelerating AI integration and hardware innovation.

Jameson Resources has cleared a key environmental hurdle for its Crown Mountain coal project in British Columbia, receiving a Section 27 Notice that sets the stage for final approvals. The company also raised A$3 million to fund the next phase of environmental assessment and Indigenous engagement.

Tissue Repair advances its US Phase III chronic wound trial with 100 patients randomised and targets October FDA 510(k) submission. The company reports a robust cash position bolstered by R&D refunds and has cut manufacturing scale-up costs.

PYC Therapeutics has made significant progress across its four RNA therapeutic programs, including dose escalation approvals in its Polycystic Kidney Disease trial and orphan drug designation for its Retinitis Pigmentosa candidate, supported by a robust cash position of $669 million.

ALS Limited reported record FY26 financial results driven by strong growth in Minerals and Industrial Materials, while advancing its digital transformation through the Lab of the Future initiative. Leadership changes and a strategic portfolio review underpin its disciplined capital allocation approach.